Results 51 to 60 of about 668,836 (354)
Pediatric Blood &Cancer, EarlyView.ABSTRACT In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within ...
Marie C. Heider +4 more
wiley +1 more source
Association Between Interleukin-12 and Sarcopenia
Journal of Inflammation Research, 2021 Yuan-Yuei Chen,1– 3 Tung-Wei Kao,3 Yi-Lin Chiu,4 Tao-Chun Peng,3 Hui-Fang Yang,3 Wei-Liang Chen3,4 1Department of Pathology, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China ...
Chen YY +5 more
doaj
Accelerated wound healing phenotype in Interleukin 12/23 deficient mice
Journal of Inflammation, 2011 Background The concept that a strong inflammatory response involving the full complement of cytokines and other mediators is critical for unimpaired healing has been challenged by wound healing studies using transgenic and knockout (KO) mice. The present
Matias Marie AT +4 more
doaj +1 more source
Interleukin-12: A master regulator [PDF]
The Journal of Experimental Medicine, 2007 Early resistance to pathogens requires a swift response from NK cells. In 1989, Giorgio Trinchieri identified an NK growth factor and activator, later called interleukin-12 (IL-12). This discovery helped reveal the regulatory link between innate and adaptive immunity.
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta +6 more
wiley +1 more source
Annals of Hepatology, 2003 Introduction: The course of HBV infection and the outcome of interferon alpha (IFNα) therapy of patients with chronic hepatitis B, is determined by the antiviral immune response of the host.
Magdalena Góra-Gębka, MD, PhD +4 more
doaj +1 more source
Immunocompetent murine models for the study of glioblastoma immunotherapy. [PDF]
, 2014 Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in ...
Bloch, Orin +9 more
core +2 more sources
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley +1 more source
Correlation Between Different Salivary Interleukins and Clinical Periodontal Parameters
Medical Journal of BabylonBackground: Periodontitis is a multifactorial disease that affects tooth-supporting structures which consequently lead to loss of tooth support and tooth loss. Interleukins showed an important role in periodontal destruction.
Sura Dakhil Jassim +2 more
doaj +1 more source
Interleukin-12 and protective immunity to schistosomes
Brazilian Journal of Medical and Biological Research, 1998 The attenuated vaccine against Schistosoma mansoni induces Th1-mediated protective immunity and we have sought to identify a role for IL-12 in this model.
A.P. Mountford, V.L. Shires, S. Anderson
doaj +1 more source